. 2019 Summer;19(2):107–115. doi: 10.31486/toj.18.0033

Table 3.

Interventional Characteristics in the Studies Included in This Metaanalysis

Study	Drug-Eluting Stent Use	Time for Secondary Procedure, days	Medical Treatment	Follow-up, months
Di Mario et al,²⁹ 2004	None; all heparin-coated Bx Velocity stents (Cordis Corporation, Cardinal Health)	Not specified	Aspirin Clopidogrel or ticlopidine	12
Politi et al,³⁰ 2010	Infarct artery:10 (11.9%) in the culprit artery only group 5 (7.7%) in the multivessel group 6 (9.2%) in the staged multivessel group	42.3 ± 22.8	Aspirin Statin Clopidogrel for 30 days if bare metal stent or 1 year if drug-eluting stent	30 ± 17
Wald et al,²⁴ 2013	Infarct artery:147 (62.8%) in the multivessel group 135 (58.4%) in the culprit artery only group Non–infarct-related artery: 165 (70.5%) in the multivessel group	40	Aspirin Clopidogrel, prasugrel, or ticagrelor Statin Beta blocker Angiotensin-converting enzyme inhibitor	23
Gershlick et al,²⁵ 2015	141 (94.0%) in the multivessel group127 (87.0%) in culprit artery only group	Not specified	Aspirin Clopidogrel, prasugrel, or ticagrel or Statin Beta blocker Angiotensin-converting enzyme inhibitor	12